Fast Five Quiz: Genetics of Non–Small Cell Lung Cancer

Daniel S. Schwartz, MD, MBA

Disclosures

February 03, 2021

KRAS subsets have vastly different biological diversity based on which co-mutations are present. It is important to identify which co-mutations are present as this will determine targeted treatment options.

Patients with KRAS-mutated NSCLC and concurrent LKB1 mutation tend to have disease resistant to immunotherapy. For this reason, some experts recommend chemoimmunotherapy to improve likelihood of a response, with the caveat that no prospective trials to date have been conducted in this patient population. If a TP53 mutation is present instead of an LKB1 mutation, then single-agent immunotherapy would be more favorable.

There are currently no targeted therapy options for patients with KRAS-mutated NSCLC; therefore, neither the EGFR TKI osimertinib nor the ALK inhibitor brigatinib are suitable treatment options for these patients.

For additional information, refer to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Non–Small Cell Lung Cancer and the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines: Lung and Chest Tumours.

Learn more about factors associated with KRAS mutation.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....